Literature DB >> 8499440

Lipid bilayer partitioning and stability of camptothecin drugs.

T G Burke1, A K Mishra, M C Wani, M E Wall.   

Abstract

The intense intrinsic fluorescence emissions from several clinically relevant camptothecin drugs have been exploited in order to determine (1) the structural basis of drug binding to lipid bilayers, (2) the lipid bilayer stability of each drug's alpha-hydroxylactone moiety, a pharmacophore which is essential for antitumor activity, and (3) the site of drug binding in the bilayer. Equilibrium affinities of camptothecin and related congeners for small unilamellar vesicles composed of electroneutral dimyristoylphosphatidylcholine (DMPC) or negatively-charged dimyristoylphosphatidylglycerol (DMPG) were determined using the method of fluorescence anisotropy titration. Experiments were conducted in phosphate-buffered saline (PBS) at 37 degrees C and overall association constants (K values) were determined. Of the seven compounds studied, the new compound 9-chloro-10,11-methylenedioxy-(20S)-camptothecin (CMC) was found to display the highest membrane affinities (KDMPC = 400 M-1, KDMPG = 320 M-1), followed by 10,11-methylenedioxy-camptothecin and camptothecin, which exhibited KDMPC and KDMPG values of 100 M-1 or greater. Topotecan displayed markedly reduced binding to lipid bilayers (KDMPC = 10 M-1, KDMPG = 50 M-1). HPLC assays were subsequently employed to assess the relative stabilities of the lactone ring of membrane-bound drugs. Our results clearly indicate that lipid bilayer interactions stabilize the lactone moiety of camptothecin drugs. In comparison to half-lives in PBS (37 degrees C) of 17 and 19 min for camptothecin and CMC, respectively, DMPC- or DMPG-bound drugs were found to be stable even for periods up to 72 h. Iodide quenching data indicate that membrane-bound camptothecin intercalates between the lipid acyl chains, in a protected environment well removed from the aqueous interface. In this manner lipid bilayer interactions stabilize the lactone ring structure of camptothecins and thereby conserve the biologically active form of each medication.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499440     DOI: 10.1021/bi00071a010

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

Review 1.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

2.  Metabolic pathways of the camptothecin analog AR-67.

Authors:  Jamie Horn; Marta Milewska; Susanne M Arnold; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

3.  Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67.

Authors:  Vijay Joguparthi; Shaoxin Feng; Bradley D Anderson
Journal:  Int J Pharm       Date:  2007-10-12       Impact factor: 5.875

Review 4.  Lipid-based drug carriers for prodrugs to enhance drug delivery.

Authors:  Jennica L Zaro
Journal:  AAPS J       Date:  2014-10-01       Impact factor: 4.009

5.  On the magnitude of the electrostatic contribution to ligand-DNA interactions.

Authors:  V K Misra; B Honig
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  A method to determine the incorporation capacity of camptothecin in liposomes.

Authors:  Ann Mari Saetern; Gøril Eide Flaten; Martin Brandl
Journal:  AAPS PharmSciTech       Date:  2004-06-17       Impact factor: 3.246

7.  Mapping topoisomerase sites in mitochondrial DNA with a poisonous mitochondrial topoisomerase I (Top1mt).

Authors:  Ilaria Dalla Rosa; Shar-Yin N Huang; Keli Agama; Salim Khiati; Hongliang Zhang; Yves Pommier
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

8.  Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.

Authors:  M E Proulx; A Désormeaux; J F Marquis; M Olivier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  Use of cilofungin as direct fluorescent probe for monitoring antifungal drug-membrane interaction.

Authors:  Y T Ko; R D Ludescher; D J Frost; B P Wasserman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

Authors:  S D Baker; R L Heideman; W R Crom; J F Kuttesch; A Gajjar; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.